- GlobeNewswire•last monthSwissmedic Accepts for Review Santhera's Marketing Authorization Application for Raxone® for the Treatment of Duchenne Muscular Dystrophy
Liestal, Switzerland, November 8, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review Santhera`s Marketing Authorization ...
- GlobeNewswire•2 months agoSanthera announces appointment of Kristina Timdahl as Chief Medical Officer and Head of Development as of January 2017
Liestal, Switzerland, October 4, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Kristina Timdahl, MD, as Chief Medical Officer and Head of Development and Member of the Executive ...
- GlobeNewswire•2 months agoSanthera Starts Phase III Study (SIDEROS) with Raxone in Patients with Duchenne Muscular Dystrophy Using Glucocorticoids
Liestal, Switzerland, September 28, 2016 - Santhera Pharmaceuticals (SIX: SANN) announces that the first patient has been enrolled at the University of Kansas Medical Center (KUMC), Department of Neurology, ...
SANN.SW : Summary for SANTHERA N - Yahoo Finance
SANTHERA N (SANN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||43.50 - 47.20|
|52 Week Range||37.05 - 91.45|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|